EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE
Main Article Content
Abstract
In 127 patients with atrial fibrillation (AF), the efficacy and safety of anticoagulant treatment for 12 months was studied. The mean age of patients was 69.9 ± 1.2 years, 41.7% were older than 75 years, and 20% had GFR <40 ml / min / 1.73 m2. The average CHA2DS2-VASc was 4.0, the average HAS- BLED is 1.8. 24 patients took dabigatran (Pradaхa) at a dose of 110-150 mg 2 times a day, 25 - apixaban (Eliquis) at a dose of 2.5-5 mg 2 times a day, 39 - rivaroxaban (Xarеlto) 20 mg per day and 39 - warfarin dose ensuring the maintenance of INR at the level of 1.8-2.5. It is proved that all three PLA are effective in preventing strokes with non-valvular AF in comparison with warfarin. The HR of stroke development in comparison with warfarin for dabigatran was 0.54, for apixaban – 0.41 and for rivaroxaban – 0.37. The risk of bleeding for dabigatran D 0.25, for apixaban – 0.04, for rivaroxaban – 0.18. Low risk of bleeding was associated with taking apaxaban at a dose of 2,5 mg 2 times a day and pradaxa 110 mg 2 times a day in individuals ≤ 75 years and/or having GFR<40 ml/min/1,73m2. Logistic regression revealed that the most significant factors for stroke development were age over 75 years, GFR below 40 ml/min/1,73m2 and the presence of previous strokes in history. For the risk of bleeding, significant risk factors were age over 75 years and GFR <40 ml/min/1,73m2.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Sulimov VA, Golicyn SP, Panchenko RP, Popov SV, Revishvili ASh, Shubik YV et al. Guidelines of Russian Cardiologic Society. Russian scientific on clinical electrophysiology, arrhythmology and Association of cardiovascular surgeons. Diagnosis and treatment of atrial fibrillation. Russian Journal of Cardiology. 2013; 4 S3: 1-100. Russian (Сулимов В.А., Голицын С.П., Панченко Е.П., Попов С.В., Ревишвили А.Ш., Шубик Ю.В. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ //Российский кардиологический журнал. 2013. Т. 18, № 4 S3. С. 1-100)
Yavelov IS, Moisseyev SV. Antithrombotic treatment in current guidelines on atrial fibrillation management. Klinicheskaya Farmakologiya i Terapiya. 2011; 20(3): 64-70. Russian (Явелов И.С., Моисеев С.В. Антитромботическая терапия в современных рекомендациях по лечению фибрилляции предсердий //Клиническая фармакология и терапия. 2011. Т. 20, № 3. С. 64-70)
Moiseev SV. The efficacy and safety of new oral anticoagulants in patients with atrial fibrillation in clinical practice. Rational Pharmacotherapy in Cardiology. 2016; 12(2): 220-226. Russian (Моисеев С.В. Эффективность и безопасность новых пероральных антикоагулянтов у больных с фибрилляцией предсердий в клинической практике //Рациональная фармакотерапия в кардиологии. 2016. Т. 12, № 2. С. 220-226)
Connoly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillatuion. N. Engl. J. Med. 2009; 361(12): 1139-1151
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in with atrial fibrillatuion. N. Engl. J. Med. 2011; 365(11): 981-992. doi: 10.1056/NEJMoa1107039
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al.; ROCET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365(10): 883-891. doi: 10.1056/NEJMoa1009638
Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost. 2018; 118(03): 526-538. doi: 10.1160/TH17-10-0733
Daabul’ IS, Sokolova AA, Napalkov DA. Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Rational Pharmacotherapy in Cardiology. 2016; 12(5): 595-602. Russian (Даабуль И.С., Соколова А.А., Напалков Д.А. Возможности современной антикоагулянтной терапии у пациентов с неклапанной этиологией фибрилляции предсердий и хронической болезнью почек //Рациональная фармакотерапия в кардиологии. 2016. Т. 12, № 5. С. 595-602)
Esayan AM. Anticoagulant therapy in patient with chronical kidney disease and atrial fibrillation. Heart Failure Journal. 2017; 18(4): 243-252. (Есаян А.М. Антикоагулянтная терапия у пациентов с хронической болезнью почек и фибрилляцией предсердий //Сердечная недостаточность. 2017. Т. 18, № 4. С. 243-252)